Sumaiya Sharmeen

Sumaiya Sharmeen is a partner at Morrison & Foerster LLP in Palo Alto, California. Her practice areas at the firm include patent litigation, IP litigation, and life sciences disputes, with industry experience in life sciences and healthcare and in biotechnology and pharmaceuticals. She was admitted to the State Bar of California in 2019 and was elected to the Morrison & Foerster partnership effective in 2026.

According to the firm, Sharmeen's matters have included representing Novartis in Hatch-Waxman litigation in the District of Delaware concerning a generic version of the Gilenya multiple sclerosis product, representing Healthgen in a patent infringement action in the District of Kansas involving recombinant human serum albumin patents, and representing Seagen in proceedings against Daiichi Sankyo involving antibody-drug conjugate technology, in which the firm reports a jury verdict of willful infringement and a $41.8 million award for Seagen. The firm also reports work for both innovators and challengers in proceedings under the Biologics Price Competition and Innovation Act.

Sharmeen has written on patent standing and enablement issues for publications including Law360 and the firm's IP Strategist, and has spoken at industry programs such as ACI's Summit on Biosimilars & Innovator Biologics. She holds a J.D. from Osgoode Hall Law School and bachelor's and master's degrees in biology from the University of Toronto.